Taysha Gene Therapies: Astellas Throws Lifeline For First Dibs On Rett And GAN Programs

Nov. 17, 2022 6:04 PM ETTaysha Gene Therapies, Inc. (TSHA)3 Comments


  • Shares have fallen by 85% since Sept 2020 IPO as cash resources dwindled to $34M as of last month.
  • Company was forced to cut 35% of workforce, stop construction of its cGMP manufacturing facility and focus on two lead clinical candidates.
  • Astellas, after seeing all available internal information and data, threw Taysha a $50M lifeline ($20M payment & $30M investment for 15% stake).
  • Bear thesis includes safety/tolerability concerns (Novartis discontinued its Rett program last year), negative FDA feedback for GAN and additional financing needs in 2023.
  • TSHA is a Speculative Buy. I see pathway to value creation via adult Rett data for full cohort of patients 1H 23 along with progress for pediatric cohort to follow.
  • Looking for a portfolio of ideas like this one? Members of ROTY Biotech Community get exclusive access to our subscriber-only portfolios. Learn More »
DNA molecule

Artur Plawgo

Shares of Taysha Gene Therapies (NASDAQ:TSHA) have fallen by 85% since the September 2020 IPO was priced at $20. Performance is an even more brutal -88% since my initial article was published in April 2021 (talk about poor timing).


Take a 2 Week Free Trial and Join 500+ biotech investors and traders in the ROTY Biotech Community!

  • Participate in a Live Chat where members generously share due diligence, top holdings and genuinely wish to see each other profit.
  • Get access to JF's highest conviction ideas, trades & updates for model portfolios, personal DCA account and all my archives for DD purposes
  • Trade to Live, NOT Live to Trade philosophy (low maintenance, follow our thesis and make changes to positions only as merited)
  • Multiple 2023 setups on radar currently trading at attractive valuations

This article was written by

Jonathan Faison profile picture
Community of Biotech Investors Focused on Value & Clinical Momentum

Founder of 500+ member ROTY Biotech Community (try the 2-week free trial to see if it adds value for you). Quality over quantity- enjoy connecting with readers.

Disclosure: I/we have a beneficial long position in the shares of TSHA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Disclaimer: Commentary presented is NOT individualized investment advice. Opinions offered here are NOT personalized recommendations. Readers are expected to do their own due diligence or consult an investment professional if needed prior to making trades. Strategies discussed should not be mistaken for recommendations, and past performance may not be indicative of future results. Although I do my best to present factual research, I do not in any way guarantee the accuracy of the information I post. I reserve the right to make investment decisions on behalf of myself and affiliates regarding any security without notification except where it is required by law. Keep in mind that any opinion or position disclosed on this platform is subject to change at any moment as the thesis evolves. Investing in common stock can result in partial or total loss of capital. In other words, readers are expected to form their own trading plan, do their own research and take responsibility for their own actions. If they are not able or willing to do so, better to buy index funds or find a thoroughly vetted fee-only financial advisor to handle your account.

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.